Curonix
Curonix is a privately-held medical device company that develops and markets battery-free implantable neurostimulation systems (Freedom PNS and SCS) using its proprietary HF-EMC technology, serving pain management physicians, orthopedic surgeons, and spine surgeons treating chronic intractable pain.
- Company typePrivate
- Founded2022
- HeadquartersPompano Beach, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Curonix does
Curonix is a privately-held medical device company that develops and markets implantable neurostimulation systems for chronic pain management. Headquartered in Pompano Beach, Florida, the company sells the Freedom platform, which comprises the Freedom Peripheral Nerve Stimulator (PNS) System and the Freedom Spinal Cord Stimulator (SCS) System. Both systems are built on Curonix's proprietary High Frequency-Electromagnetic Coupling (HF-EMC) technology, which delivers power through the skin from an external transmitter to a battery-free implanted receiver, eliminating the need for implanted batteries and the associated pocket pain, replacement surgeries, and IPG-related complications. The platform is complemented by NervPulse Therapy — a nerve-specific programming module with therapy programs for 33 peripheral nerves — and a family of purpose-built wearables (Extremity, Torso, Upper Torso, and Head/Neck) designed for different anatomical indications.
Curonix serves healthcare providers across multiple specialties, including pain management physicians, interventional pain specialists, orthopedic surgeons, spine surgeons, and interventional radiologists, who implant the Freedom systems in patients suffering from chronic intractable pain of peripheral nerve and spinal origin. The company reports more than 20,000 patients treated and 30,000 cumulative Freedom PNS procedures, supported by a clinical evidence base of 44 publications covering 495+ study patients. Curonix also operates Curonix Connect, a reimbursement support platform providing insurance verification, prior authorization, and appeals assistance that is integral to provider adoption given the complexity of neurostimulation reimbursement. As of April 2026, expanded reimbursement coverage provides access to an additional 27 million covered lives.
Curonix operates a direct enterprise field sales model targeting healthcare providers in the United States, with international websites supporting English and German-speaking markets. Devices are sold to providers who then bill payers, including Medicare and commercial plans, on a quote-based pricing model that is not publicly disclosed. The go-to-market is reinforced by national and international bioskills training courses featuring didactic and cadaveric instruction, conference presence at ASPN and AOFAS, comprehensive website content for both providers and patients, and a physician locator tool that drives patient referrals to provider customers. Curonix holds an extensive U.S. patent portfolio covering its electrode arrays, external transmitters, antennas, and wearable components, and operates under AdvaMed Code of Ethics compliance.
Curonix firmographics
Firmographics- Name
- Curonix
- Legal name
- Curonix LLC
- Website
- https://curonix.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Curonix is a privately-held medical device company that develops and markets battery-free implantable neurostimulation systems (Freedom PNS and SCS) using its proprietary HF-EMC technology, serving pain management physicians, orthopedic surgeons, and spine surgeons treating chronic intractable pain.
- Ownership category
- akta.pro rank
Curonix industry classification
Industry- Product category
- Implantable Neurostimulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
Keywords
Where Curonix is headquartered
LocationHeadquarters
- HQ city
- Pompano Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Curonix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
Revenue model
- Medical Device Sales: Curonix generates revenue through the sale of its Freedom PNS and Freedom SCS implantable neurostimulation systems. The systems are two-component permanent implant systems that include electrode arrays, implanted receivers, external transmitter assemblies, and wearable accessories. Revenue is generated through healthcare providers who implant the devices in patients suffering from chronic pain conditions.
- Professional Services - Reimbursement Support: Curonix offers reimbursement support services through Curonix Connect, including insurance verification, prior authorization, and appeals support. While primarily a customer service function to facilitate device access, these services may generate professional services revenue through healthcare economics consulting.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | CustomQuote - Procedure and product pricing determined based on specific patient needs and payer coverage |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Curonix product offering
Product offeringCore offering
Curonix manufactures and distributes FDA-cleared implantable neurostimulation systems for chronic pain management. Its core Freedom System platform consists of two-component permanent implant devices — the Freedom Peripheral Nerve Stimulator (PNS) System and Freedom Spinal Cord Stimulator (SCS) System — that use proprietary High Frequency-Electromagnetic Coupling (HF-EMC) technology to power the implanted receiver through the skin without an implanted battery. The company sells directly to healthcare providers and supports them with reimbursement services through Curonix Connect.
Product overview
Curonix offers the Freedom® System platform, a family of neurostimulation products for chronic pain management. The platform consists of two core products: the Freedom Peripheral Nerve Stimulator (PNS) System for peripheral nerve pain and the Freedom Spinal Cord Stimulator (SCS) System for trunk and lower limb pain. Both systems share a common technology architecture using High Frequency-Electromagnetic Coupling (HF-EMC) that eliminates the need for implanted batteries by powering the device through the skin. The platform includes the NervPulse™ Therapy module for nerve-specific programming with 33 therapy programs, multiple electrode array configurations (4-contact and 8-contact), external transmitter assemblies, and purpose-built wearable accessories (Extremity, Torso, Upper Torso, and Head/Neck wearables). The system also includes the Curonix Connect reimbursement support platform.
Differentiator
Problem solved
Functional benefit
Brands
- Freedom: Freedom PNS (Peripheral Nerve Stimulator) System and Freedom SCS (Spinal Cord Stimulator) System - two-component permanent implant systems using HF-EMC technology for chronic pain relief.
- NervPulse
Products and services
- Freedom Peripheral Nerve Stimulator (PNS) System A two-component permanent implant system for chronic pain relief that includes an electrode array, separate implanted receiver, external transmitter assembly, and wearable accessory. Uses High Frequency-Electromagnetic Coupling (HF-EMC) technology to power the implanted neurostimulator through the skin without an implanted battery. Indicated for chronic intractable pain of peripheral nerve origin including post-surgical pain, mononeuropathies, knee, foot, ankle, shoulder, head, neck, and craniofacial pain.
- Freedom Spinal Cord Stimulator (SCS) System
Quantifiable outcome
- 47% medication reduction at 24 months post-implant
- +6 more outcomes
Companies that use Curonix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Curonix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Curonix partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
Curonix competitors and assessment
Company assessmentEmerging players
- Saluda Medical: Saluda Medical is developing closed-loop SCS technology with significant clinical evidence, positioning it as an emerging competitor in the spinal cord stimulation space where Curonix's Freedom SCS also competes.
- Mainstay Medical: Mainstay Medical offers the ReActiv8 restorative neurostimulation system for chronic low back pain, targeting a partially overlapping patient population with Curonix's SCS for intractable back and leg pain.
Direct peers
- Nevro Corp: Nevro markets the Senza spinal cord stimulation system, including 10 kHz HF therapy, and is a direct competitor to Curonix's Freedom SCS in the chronic pain neurostimulation market with the same target prescribers and payors.
- SPR Therapeutics: SPR Therapeutics markets the SPRINT PNS System for peripheral nerve stimulation, directly competing with Curonix's Freedom PNS for the same pain management and orthopedic indications.
- Axonics: Axonics markets the r-SNM sacral neuromodulation system and is developing expansion indications in chronic pain, making it a relevant neuromodulation peer using similar battery-life and miniaturization design philosophies.
- Nalu Medical: Nalu Medical offers a battery-free, externally-powered implantable neurostimulator for chronic pain, directly competing with Curonix's HF-EMC battery-free architecture in the PNS market.
Broad incumbents
- Medtronic: Medtronic is the largest neuromodulation incumbent offering the Intellis and Vanta spinal cord stimulators and a broad DBS portfolio, competing with Curonix across multiple neurostimulation segments with deep payor relationships.
- Boston Scientific: Boston Scientific offers the WaveWriter and Precision Spectra SCS systems and a deep neuromodulation portfolio, competing with Curonix across chronic pain with a larger sales force and broader payer contracts.
- Abbott: Abbott (formerly St. Jude Medical) markets the Proclaim SCS and DRG systems for chronic pain, competing with Curonix's Freedom SCS using established sales coverage in pain management and neurosurgery.
- Biotronik: Biotronik markets the Prospera and Acticor SCS systems for chronic pain, competing with Curonix's Freedom SCS through European and US sales channels with established physician relationships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Curonix social profiles
Digital presenceCuronix compliance and trust
Trust signalCompliance2 records
Curonix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curonix leadership team
Management profileNumber of profiles
Profiles9 records
Curonix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curonix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curonix
What does Curonix do?
Curonix manufactures and distributes FDA-cleared implantable neurostimulation systems for chronic pain management. Its core Freedom System platform consists of two-component permanent implant devices — the Freedom Peripheral Nerve Stimulator (PNS) System and Freedom Spinal Cord Stimulator (SCS) System — that use proprietary High Frequency-Electromagnetic Coupling (HF-EMC) technology to power the implanted receiver through the skin without an implanted battery. The company sells directly to healthcare providers and supports them with reimbursement services through Curonix Connect.
Is Curonix a public or private company?
Curonix is a private company. It is classified as unknown and is currently operating.
When was Curonix founded?
Curonix was founded in 2022. It employs 101 to 250 people.
Where is Curonix based?
Curonix is headquartered in Pompano Beach, United States, in the North America region.
How does Curonix make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are professional Services - Reimbursement Support.
Who are Curonix's main competitors?
Emerging players on record are Saluda Medical and Mainstay Medical. Direct peers are Nevro Corp, SPR Therapeutics, Axonics and Nalu Medical. Broad incumbents are Medtronic, Boston Scientific, Abbott and Biotronik.
Does Curonix have an API?
No public API is recorded for Curonix.
What industry is Curonix in?
Curonix's product category is Implantable Neurostimulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.